# People Using GLP-1s Like Ozempic and Wegovy Exercise Less, Study Finds
New research reveals a troubling pattern: people taking GLP-1 receptor agonists for weight loss exercise significantly less than those not using the medications, even though physical activity remains vital for long-term health.
GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) have transformed weight-loss treatment. They suppress appetite and slow stomach emptying, making patients feel fuller longer. Weight loss arrives quickly and dramatically. But this success may create a false sense that medication alone solves the problem.
The research examined exercise patterns among GLP-1 users and found they moved less frequently and with lower intensity compared to people managing weight through diet and exercise alone. Researchers worry this pattern sets users up for future health complications.
Exercise does more than burn calories. Regular physical activity strengthens bones, improves cardiovascular health, enhances mental wellbeing, and builds muscle mass. Rapid weight loss from GLP-1s without accompanying exercise can actually accelerate muscle loss. This matters because lean muscle supports metabolism and protects bones, especially as people age.
Doctors stress that GLP-1 medications work best alongside lifestyle changes, not instead of them. Patients should view these drugs as tools supporting healthier habits, not replacements for them. The medication removes one barrier to weight loss. Physical activity remains essential for sustained results and overall wellness.
Parents considering GLP-1s for themselves or teenagers should discuss exercise expectations with their doctors. A realistic plan combines medication with regular movement, strength training, and nutritious eating. Building these habits early creates lasting benefits long after medication use ends.
The takeaway is straightforward: GLP-1 drugs deserve credit for helping people lose